10 countries that take Hydroxychloroquine as first defense against the corona virus has a death rate of one third compared to the rest of the world, and recoveries are faster too.

Washington (CNN)Dr. Anthony Fauci said Wednesday that data shows hydroxychloroquine is not an effective treatment for the coronavirus, disputing use of the drug to fight the deadly virus even as President Donald Trump touts it as a potential cure and says he has taken it himself.

“The scientific data is really quite evident now about the lack of efficacy for it,” Fauci, a key medical adviser on the White House coronavirus task force, told CNN’s Jim Sciutto on “Newsroom” of the drug, adding that there’s likelihood of “adverse events with regard to cardiovascular.”
Dr Fauci, how do you explain the excellent results in more than 10 countries, where HCQ  is taken (Sometimes together with Azithromycine and sometimes with added Zinc) as soon as COVID-19 symptoms shows up, sometimes before a positive test is confirmed?

This is a very interesting chart:

But wait. Not so fast. These countries may have a younger population, and the death rate is much lower for younger people. This chart tells the relative death rate, and it shows that with the advent of the coronavirus the death risk doubled regardless of the age of the victim.

The death rate doubles for every 8 years as you age or about 9% per year. The world median age is 30.4 years. So let the world death rate be the norm

World death rate as of May 21 is 6.42% of diagnosed cases. and recovered cases versus deaths is 7.05

Compare this with 10 countries that use HCQ for most patients as soo as they test positive for the corona virus.

Turkey: Death rate 2.84%, median age 30.9, adjusted death rate 2.72%, recovered cases versus deaths  27.7

South Korea: Death rate 2.37%, median age 30.9, adjusted death rate 2.26% recovered cases versus deaths  38.4

Malaysia: Death rate 1.51%, median age 28.5, adjusted death rate 1.74% recovered cases versus deaths  53.6

Senegal: Death rate 1.16%, median age 18.8, adjusted death rate 3.10%, recovered cases versus deaths  43.2

Costa Rica: Death rate 1.02%, median age 31.3, adjusted death rate 0.95%, recovered cases versus deaths  63.9

United Arab emirates: Death rate 0.80%, median age 30.9, adjusted death rate  0.77%, recovered cases versus deaths  64.7

Bahrain: Death rate 1.50%, median age 32.3, adjusted death rate 1.30%, recovered cases versus deaths  353.0

Morocco: Death rate 2.65%, median age 29.3, adjusted death rate 2.88%, recovered cases versus deaths  25.3

Russia: Death rate 1.00%, median age 30.9, adjusted death rate 0.95%, recovered cases versus deaths  36.5

Qatar: Death rate 0.07%, median age 30.9, but since 88% of the population are migrant workers between 20 and 60, the adjusted death rate is at least 8 times higher, or 0.56 %, and recovered cases versus deaths  466.3

Taking the average, not adjusted for the size of the populations we get the average adjusted death rate for countries, where people are taking HCQ + Zinc when diagnosed positive, is 1.89%.

This means that the risk of death is reduced by a factor of 3.4 if HZQ + Zinc is taken as early as possible after a positive diagnosis for coronavirus!

Recovered cases versus deaths is an indicator of how fast patients recover after taking HCQ. Taking the arithmetic average would be unfair, so here I show the median recovery ratio, or about 40, compared to the recovery rate for the rest of the world of 7.05, an improvement of 5.6 times as many earlier recoveries.

What are we waiting for, and what is your concern, Dr Fauci? Hydroxychloroquine is approved for Malaria, Lupus and Rheumatoid Arthritis, and is used by millions or people world wide with normal precautions. There are side-effects, but death is not one listed, and the cardiac concern is taken care of with a simple ECG, disqualifying less than 1% of the patients.

WHO paused a double blind study out of an “abundance of caution”.

Is HCQ too cheap to promote?

I for one want to save lives.

 

Hydroxychloroquine + Zinc is the answer? Check the death rates of nine countries that use it.

This is a very interesting chart:

But wait. Not so fast. These countries have a younger population, and the death rate is much lower for younger people. This chart tells it all.

The death rate doubles for every 8 years as you age or about 9% per year. The world median age is 30.4 years. So let the world death rate be the norm

World death rate as of May 21 is 6.42% of diagnosed cases.

Turkey: Death rate 2.77%, median age 30.9, adjusted death rate 2.64%

South Korea: Death rate 2.37%, median age 30.9, adjusted death rate 2.26%

Malaysia: Death rate 1.61%, median age 28.5, adjusted death rate 1.91%

Senegal: Death rate 1.13%, median age 18.8, adjusted death rate 3.00%

Costa Rica: Death rate 1.11%, median age 31.3, adjusted death rate 1.02%

United Arab emirates: Death rate 0.88%, median age 30.9, adjusted death rate 0.84%

Bahrain: Death rate 1.43%, median age 32.3, adjusted death rate 1.20%

Morocco: Death rate 2.70%, median age 29.3, adjusted death rate 2.92%

Russia: Death rate 1.00%, median age 30.9, adjusted death rate 0.95%

Taking the average, not adjusted for the size of the populations we get the average adjusted death rate for countries, where people are taking HCQ + Zinc when diagnosed positive, is 1.89%.

This means that the risk of death is reduced by a factor of 3.4 if HZQ + Zinc is taken as early as possible after a positive diagnosis for coronavirus!

These 9 countries are living proof of it. Why are we not implementing it today?

 

 

 

President Trump is taking hydroxychloroquine! The international results are overwhelming, he is right!

In 2005 Dr. Anthony Fauci,the director of the (NIAID) National Institute of Allergy and Infectious Diseases, a position he still holds received the encouraging news that Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. The SARS epidemic petered out, ao the clinical trial was never executed.

Now the news about the efficacy of HydroxyChloroquine is coming in hot and heavy. The results are very encouraging. This is from a recent study in Marseilles, France:

We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days).

Results

A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years – range 14–95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision).

Conclusion

Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.

Since then, prescriptions for the drug cocktail in Marseilles is up 7000%, and is also increasing in the rest of France, especially the Paris region.

But France is by no means the first country to go all out prescribing the drug cocktail. At least twelve countries are doing it, and Turkey and Morocco prescribe it to all with COVID-19 symptoms ( after first checking their heart). Russia joined six weeks later. Here are the results:

If we look at the results from onset to today, some interesting facts stand out

Turkey: Death rate 50 per million. ratio of recovered cases/death is 37

Morocco: Death rate 5 per million. ratio of recovered cases/death is 19.6

Russia: Death rate 19 per million. ratio of recovered cases/death is 19.6 and rising, but they started six weeks later and have not yet reached their infection maximum.

France: Death rate 433 per million. ratio of recovered cases/death is 2.2, but their new case maximum was 11 weeks ago and the maximum death rate was 9 weeks ago, way before any prescriptions increased.

U.S. does not do an even job of reporting recovered cases, so the results will only be valid for some states. Michigan seems to be one state that records recoveries.

Michigan: Death rate 492 per million. ratio of recovered cases/death is 5.7

The best state is South Dakota, but there Governor Kristi Noem conducted a semi clinical (not double blind) trial, and the results speak for themselves.

South Dakota: Death rate 50 per million. ratio of recovered cases/death is 63.27 !!

My suggestion is this: Give the HCQ+ AZT + Zinc +Vitamin D for 5 days as soon as symptoms occur. Give HZQ + Zinc + Vitamin D for 5 days to all the infected person’s contacts, then their quarantine is over, otherwise it is 14 days. Check for heart rhythm problems, but otherwise go ahead.

The results from Turkey + Russia + Morocco  involved more than 170,000 recovered cases, far more than any clinical study, and showed the effect both before and after HCQ became the drug of choice, so the effect is real enough!

Was Sweden right? Social distancing is better than stay at home and lockdown of the economy

Sweden and New Jersey are about the same size population wise, Sweden has 10 million people, New Jersey has about 9.2 million. For both, the foreign born population is about 20 percent. When the coronavirus pandemic hit they took quite different action at the same time:

New Jersey went into full lockdown with a near complete halt to the economy.

Sweden issued social distancing, crowds and travel restrictions, and hygiene regulations, but kept businesses and restaurants open within limits.

Yer their death rates followed the same bell curve as the disease marched on

 

Yet, there was one big difference, the deaths from the corona virus  was three times larger in New Jersey than in Sweden, the total cases was five times larger.

It is always touted that we need more testing, New Jersey has made 451,696 tests, Sweden only 177,500. More testing will find more mild and asymptomatic cases, but the deaths will be the same.

The solution is to let the young and healthy develop herd immunity, but protect the vulnerable, such as the old, obese, diabetic, people with hypertension, weak hearts or a compromised immune system.

 

 

Coronavirus death rates and trends for the five worst states versus the five best states. Look at Michigan versus South Dakota.

The trend of the five worst and the five best states of Covid-19 death rates versus percent of population tested:

State                     death rate               trend   percentage of population tested

.                             May 8      May 11  up/down     May 8   May 11

  1.  Michigan              9.48%        9.64%    up                2.4%       3.1%

2.  Connecticut      8,87%        8.91%   up                3.1%        3.7%

3.  New York          7.80%        7.80%     __                 5.6%      6.2%

4.  Lousiana           7.23%       7.32%     up                 4.4%      4.9%

5.  New Jersey       6.55%       6.71%     up                 4.4%      4.9%

….

46. Tennessee         1.66%      1.61%    down             3.4%       4.0%

47. Nebraska           1.17%       1.16%  down             2.0%        2.5%

48. Wyoming           1.08%      1.05%   down            2.1%         2.3%

49. Utah                    1.03%       1.06%  up                 4.3%          4.7%

50. South Dakota     0.98%      0.94%   down            2.4%         2.7%

Beside from the obvious fact that the five worst states are all run by Democrat Governors and the five best state are all run by Republicans, these are my observations:

The five worst states show a rising death rate, even though the test rate is increasing. The five best state show a falling death rate, which is to be expected as testing is increased.

Michigan has a Detroit problem. The COVID-19 death rate there is over 10%, many got turned away from the few hospitals and were sent home without first being tested. Governor Gretchen Whitmer seems more interested in controlling the healthy population than to protect the vulnerable.

Why Connecticut is second on the list I don’t know, but Hartford County has a problem with a death rate over 10%. It is also next to New York, where the death rate in New York City still is either 7.92% or 10.7% if you include probable deaths.

The problem with New York is that Governor Cuomo ordered nursing home facilities to accept COVID-19 patients, they are not set up to handle highly contagious patients, and so the infection and death rate among the most vulnerable population skyrocketed. One interesting statistics is that two thirds of all New York COVID-19 cases were from people staying home, not going out at all.

The problem with Louisiana is that it let Mardi Gras proceed, people came, did their thing and went back to where they came from, often to under-served areas.

New Jersey is next to New York. Need I say more?

On the other hand, the five best states concentrated their efforts to protect the at risk people, concentrating on hygiene and social distancing rather than trying to micromanage the healthy population. There seems to be no improvement in the outcome by adding testing. In addition the death rate among the five worst states is still rising, whereas the death rate in the five best states is declining.

Governor Kristi Noem of South Dakota, the state with the best outcome of all states so far did order a clinical test of using the combination Hydroxychloroquine + Azithromycin + Zinc for five days and that may be the reason the death rate is less than 1 percent. Unfortunately the FDA is concerned that hydroxychloroquine and chloroquine are being used inappropriately to treat non-hospitalized patients for coronavirus disease (COVID-19) or to prevent that disease.  Quote:” We authorized their temporary use only in hospitalized patients with COVID-19 when clinical trials are not available, or participation is not feasible, through an Emergency Use Authorization (EUA).  These medicines have a number of side effects, including serious heart rhythm problems that can be life-threatening.”

Here is my suggestion: Issue an executive order opening up a clinical study in the effectiveness of COVID-19 treatment with Hydroxychloroquine + Azithromycin + Zinc for five days, and open it up to any qualified Physician or Nurse Practitioner who want to participate. They do the heart test, check for other ailments and report the results to a central data base and a follow up report, and even if it is not a double blind study, once you have a million or so results the FDA can approve the medication. In the meantime over 90% of the patients were getting better, and hopefully nobody had given it to patients with severe preexisting heart conditions. The risk is minimal. It is already approved for Lupus, Rheumatism and Malaria, and the same protocol should apply here.

It is very important the drugs are administered as early as possible. By the time the patient is admitted to a hospital it may be too late. Especially if the patient is already on a ventilator it may do more harm than good.

Why is this study even necessary? This medication is too cheap, it is generic, so no pharmaceutical company is willing to foot the bill on something unprofitable, so it must be done by a university or through a government agency.

It is not that daring a thing to do. Here is a result of a COVID-19 study with more than 6,200 physicians in 30 countries.

  • The three most commonly prescribed treatments among COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine
  • Hydroxychloroquine usage among COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in the U.S., 17% in Germany, 16% in Canada, 13% in the UK and 7% in Japan
  • Hydroxychloroquine was overall chosen as the most effective therapy among COVID-19 treaters from a list of 15 options (37% of COVID-19 treaters)
    • 75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in the U.S. and 13% in the U.K.
  • The two most common treatment regimens for Hydroxychloroquine were:
    • (38%) 400mg twice daily on day one; 400 mg daily for five days
    • (26%) 400mg twice daily on day one; 200mg twice daily for four days
  • Outside the U.S., Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the U.S. it was most commonly used for high risk diagnosed patients
  • Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients.

And this is a very recent tweet from president Donald Trump, without which frequent and persistent recommendation this drug combination would have already been approved, as it is in at least 12 other countries.

  • Hcq

 

Make a nationwide clinical test of using the combination Hydroxychloroquine + Azithromycin + Zinc for five days to treat COVID-19 patients. It will save lives!

The five worst and the five best states of Covid-19 death rates versus percent of population tested:

  1.  Michigan              9.48% death rate and 2.4% of population tested

2.  Connecticut      8,87%                            3.1%

3.  New York          7.80%                            5.6%

4.  Lousiana           7.23%                            4.4%

5.  New Jersey       6.55%                            4.4%

….

46. Tennessee         1.66%                            3.4%

47. Nebraska           1.17%                            2.0%

48. Wyoming           1.08%                            2.1%

49. Utah                    1.03%                            4.3%

50. South Dakota     0.98%                            2.4%

Beside from the obvious fact that the five worst states are all run by Democrat Governors and the five best state are all run by Republicans, these are my observations:

Michigan has a Detroit problem. The COVID-19 death rate there is over 10%, many got turned away from the few hospitals and were sent home without first being tested. Governor Gretchen Whitmer seems more interested in controlling the healthy population than to protect the vulnerable.

Why Connecticut is second on the list I don’t know, but Hartford County has a problem with a death rate over 10%

The problem with New York is that Governor Cuomo ordered nursing home facilities to accept COVID-19 patients, they are not set up to handle highly contagious patients, and so the infection and death rate among the most vulnerable population skyrocketed. One interesting statistics is that two thirds of all New York COVID-19 cases were from people staying home, not going out at all.

The problem with Louisiana is that it let Mardi Gras proceed and people came, did their thing and went back to where they came from, often to under-served areas.

New Jersey is next to New York. Need I say more?

On the other hand, the five best states concentrated their efforts to protect the at risk people, concentrating on hygiene and social distancing rather than trying to micromanage the healthy population. There seem to be no improvement in the outcome by adding testing. In addition the death rate among the five worst states is still rising, whereas the death rate in the five best states is declining.

Governor Kristi Noem of South Dakota, the state with the best outcome so far did order a clinical test of using the combination Hydroxychloroquine + Azithromycin + Zinc for five days and that may be the reason the death rate is less than 1 percent. Unfortunately the FDA is concerned that hydroxychloroquine and chloroquine are being used inappropriately to treat non-hospitalized patients for coronavirus disease (COVID-19) or to prevent that disease.  Quote:” We authorized their temporary use only in hospitalized patients with COVID-19 when clinical trials are not available, or participation is not feasible, through an Emergency Use Authorization (EUA).  These medicines have a number of side effects, including serious heart rhythm problems that can be life-threatening.”

Here is my suggestion: Issue an executive order opening up a clinical study in the effectiveness of COVID-19 treatment with Hydroxychloroquine + Azithromycin + Zinc for five days, and open it up to any qualified Physician or Nurse Practitioner who want to participate. They do the heart test, check for other ailments and report the results to a central data base and a follow up report, and even if it is not a double blind study, once you have a million or so results the FDA can approve the medication. In the meantime over 90% of the patients were getting better, and hopefully nobody had given it to patients with severe preexisting heart conditions. The risk is minimal. It is already approved for Lupus, Rheumatism and Malaria, and the same protocol should apply here.

It is very important the drug is administered as early as possible. By the time the patient is admitted to a hospital it may be too late. Especially if the patient is already on a ventilator it may do more harm than good.

Why is this study even necessary? This medication is too cheap, it is generic, so no pharmaceutical company is willing to foot the bill on something unprofitable, so it must be done by a university or through a government agency.

It is not that daring a thing to do. Here is a result of a COVID-19 study with more than 6,200 physicians in 30 countries.

  • The three most commonly prescribed treatments among COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine
  • Hydroxychloroquine usage among COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in the U.S., 17% in Germany, 16% in Canada, 13% in the UK and 7% in Japan
  • Hydroxychloroquine was overall chosen as the most effective therapy among COVID-19 treaters from a list of 15 options (37% of COVID-19 treaters)
    • 75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in the U.S. and 13% in the U.K.
  • The two most common treatment regimens for Hydroxychloroquine were:
    • (38%) 400mg twice daily on day one; 400 mg daily for five days
    • (26%) 400mg twice daily on day one; 200mg twice daily for four days
  • Outside the U.S., Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the U.S. it was most commonly used for high risk diagnosed patients
  • Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients.

And this is a very recent tweet from president Donald Trump, without which frequent and persistent recommendation this drug combination would have already been approved, as it is in at least 12 other countries.

  • Hcq

 

HZQ-AZ-Z 5 day cheap cure to early COVID-19 onset is over 90% effective. Why not approve it now?

Remdesivir Just Became The First Drug to Show a ‘Clear-Cut’ Effect in Treating COVID-19

ISSAM AHMED, AFP
30 APRIL 2020

COVID-19 patients on the antiviral remdesivir recovered about 30 percent faster than those on a placebo, the results of a major clinical trial showed Wednesday, as a top US scientist hailed the drug’s “clear-cut” benefit.

This was touted as a major breakthrough by Dr Fauci in a Presidential briefing yesterday, and indeed, it seems to show efficacy. Patients on the drug, made by Gilead Sciences, had a 31 percent faster time to recovery than those on a placebo. “Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo,” it said. The results also suggested that people who were on the drug were less likely to die, although the difference was quite small. The mortality rate was 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group.

On the other hand the FDA issued a warning for using the drug-combination HydroxyChloroQuine + AZithromycin + Zinc. AZ was approved in 1988, HCQ has been approved for malaria in over 50 years, and for Lupus and Rheumatism for decades, and all that requires for prolonged use is that an EKG is taken periodically to check for possible heart arrhythmia. It is an easy 5 day application and it shows good outcome in 91.7%  of 1061 patients. Poor outcome was observed by 4,7% and in 0,47% the patient died. The age of those who died was 74 – 95 years old. If they had not taken this medication the death rate for people of that age is 5 – 8%. This is taken from the famous Marseille study.

Sequential CQ / HCQ Research Papers and Reports

January to April 20, 2020

Executive Summary Interpretation of the Data In This Report

The HCQ-AZ combination, when started immediately after diagnosis, appears to be a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagious infectivity in most cases.

A cohort of 1061 COVID-19 patients, treated for at least 3 days with the HCQ-AZ combination and a follow-up of at least 9 days was investigated. Endpoints were death, worsening and viral shedding persistence. From March 3rd to April 9th, 2020, 59,655 specimens from 38,617 patients were tested for COVID-19 by PCR. Of the 3,165 positive patients placed in the care of our institute, 1061 previously unpublished patients met the inclusion criteria for a Hydroxychloroquine –Azithromycin trial.

Mean age was 43.6 years old and 492 were male (46.4%), As in other studies, no cardiac toxicity was observed in this study.

 

  • A good clinical outcome and virological cure was obtained in 973 patients out of a total pf 1061 patients within 10 days (91.7%).

 

  • Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens both at IHU and in all Marseille public hospitals

A poor outcome was observed for 46 patients (4.3%); –10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old), 31 required 10 days of hospitalization or more.

Among this group, 25 patients are now cured and 16 are still hospitalized (98% of patients cured so far). 

Why the different approaches to these two medications?

Most of the rest of the world are jumping on the HCQ-AZ-Z opportunity. Why not US?